Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.

Clinical pharmacokinetics - 1 Oct 2016

Sutiman Natalia, Lim Joanne Siok Liu, Muerdter Thomas E, Singh Onkar, Cheung Yin Bun, Ng Raymond Chee Hui, Yap Yoon Sim, Wong Nan Soon, Ang Peter Cher Siang, Dent Rebecca, Schroth Werner, Schwab Matthias, Khor Chiea Chuen, Chowbay Balram

Abstract excerpt

Tamoxifen (TAM) is an established endocrine treatment for all stages of oestrogen receptor (ER)-positive breast cancer. Its complex metabolism leads to the formation of multiple active and inactive metabolites. One of the main detoxification and elimination pathways of tamoxifen and its active metabolites, 4-hydroxytamoxifen (4-OHT) and endoxifen, is via glucuronidation catalysed by uridine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Asian People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Cytochrome P-450 CYP2D6

Share to Ethnicity

Share to Glucuronosyltransferase

Share to Pharmacogenetics

Share to Tamoxifen

Source

Identifiers

PMID: 27098059
DOI: 10.1007/s40262-016-0402-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.PMID 27098059Read ↗

Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.Semantic proximity Read ↗

Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.Semantic proximity Read ↗

Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites.Semantic proximity Read ↗

A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives.Semantic proximity Read ↗

Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.Semantic proximity Read ↗

Association Analysis among Tamoxifen Metabolites and Genetic Polymorphisms in Hormone-Dependent Chilean Breast Cancer Patients: A Preliminary StudySemantic proximity Read ↗

Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, EndoxifenSemantic proximity Read ↗

Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.Semantic proximity Read ↗

Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.Semantic proximity Read ↗

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of TamoxifenSemantic proximity Read ↗

Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.